Making the Investment Case: Cost-effectiveness Evidence for Harm Reduction
May 5, 2020

Making the Investment Case: Cost-effectiveness Evidence for Harm Reduction

HIV continues to rise among people who inject drugs, yet harm reduction funding is in crisis. Financial support for an effective HIV response for people who inject drugs in low- and middle-income countries totalled US$188 million in 2016 – just one-tenth of the US$1.5 billion that is needed annually by 2020. 

Organizations:

Harm Reduction International (HRI)

Share article: